BMI1 and non-small cell lung carcinoma: Finally, the mouse orthotopic model demonstrated that co-administration of a BMI1 inhibitor with Bevacizumab enhances the anti-cancer efficacy of Bevacizumab in NSCLC, suggesting new avenues for clinical application.